Mutations and other changes in protein p53 and its dependent pathways as part of both G1 and G2/M checkpoint signaling have also been detected in GBM, although their frequency and importance for development and maintenance of malignant phenotype differ in relation to the GBM type [64,65]. This evidence concerns the gene TP53 and glioblastoma.